662
Views
20
CrossRef citations to date
0
Altmetric
Original Articles

A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017

, ORCID Icon, , ORCID Icon, ORCID Icon, , ORCID Icon & ORCID Icon show all
Pages 74-83 | Received 23 Feb 2020, Accepted 09 Jul 2020, Published online: 24 Nov 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Elisabeth Prevete, Valeria Catalani, Darshan Singh, Kim P. C. Kuypers, Eef L. Theunissen, Honor D. Townshend, Hani Banayoti, Johannes G. Ramaekers, Massimo Pasquini & Ornella Corazza. (2023) A Preliminary Inventory of Kratom (Mitragyna Speciosa) Products and Vendors on the Darknet and Cryptomarkets. Journal of Psychoactive Drugs 0:0, pages 1-11.
Read now
Kirsten E. Smith, Jeffrey M. Rogers & Justin C. Strickland. (2022) Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample. Journal of Psychoactive Drugs 54:5, pages 429-439.
Read now
Cornel Stanciu, Saeed Ahmed, Samantha Gnanasegaram, Stephen Gibson, Thomas Penders, Oliver Grundmann & Christopher McCurdy. (2022) Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature. The American Journal of Drug and Alcohol Abuse 48:5, pages 509-528.
Read now
Mike C. Parent, Nathaniel W. Woznicki & Jackie Yang. (2022) Demographic and behavioral factors associated with kratom use among U.S. college students. Journal of American College Health 0:0, pages 1-5.
Read now
Fatemeh Chichagi, Reyhaneh Alikhani & Asghar Beigi Harchegani. Cardiovascular health in kratom users; a narrative review. Journal of Addictive Diseases 0:0, pages 1-13.
Read now

Articles from other publishers (15)

Maximilian Gahr. (2022) Kratom (Mitragyna speciosa): eine psychoaktive Pflanze mit Chancen und Risiken. Fortschritte der Neurologie · Psychiatrie 91:11, pages 455-465.
Crossref
Oliver Grundmann, Robert G. Hendrickson & Michael I. Greenberg. (2023) Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. Disease-a-Month 69:6, pages 101442.
Crossref
Kirsten Elin Smith, Jeffrey M. Rogers & Jeffrey D. Feldman. (2023) Kratom’s Emergence and Persistence Within the US Polydrug Epidemic. Current Addiction Reports 10:2, pages 262-271.
Crossref
Kirsten E. Smith, Jeffrey D. Feldman, Destiny Schriefer, Stephanie T. Weiss, Oliver Grundmann, Kelly E. Dunn, Darshan Singh, Christopher R. McCurdy, Gisela Butera & David H. Epstein. (2023) Diagnostic Ambiguities and Underuse of Clinical Assessment Tools: A Systematic Review of Case Reports on Kratom Addiction and Physical Dependence. Current Addiction Reports 10:2, pages 282-292.
Crossref
David Peran, Michael Stern, Petr Cernohorsky, Roman Sykora, Stanislav Popela & Frantisek Duska. (2023) Mitragyna speciosa (Kratom) poisoning: Findings from ten cases. Toxicon 225, pages 107054.
Crossref
Corneliu N. Stanciu, Samantha A. Gnanasegaram, Gerald L. RaderIIIIII, Abhisheak Sharma & Christopher R. McCurdy. (2023) What Is the Kratom Overdose Risk? A Systematic Literature Review. Current Addiction Reports 10:1, pages 9-28.
Crossref
Mona A. Raslan. (2022) Natural Products for the Treatment of Drug Addiction: Narrative Review. Chemistry & Biodiversity 19:12.
Crossref
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, Albert Garcia-Romeu, Justin C. Strickland & David H. Epstein. (2022) Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults. Journal of Addiction Medicine 16:6, pages 666-670.
Crossref
David A. Gorelick. (2022) Kratom: Substance of Abuse or Therapeutic Plant?. Psychiatric Clinics of North America 45:3, pages 415-430.
Crossref
Walter Prozialeck, Alexandra Fowler & Joshua Edwards. (2022) Public Health Implications and Possible Sources of Lead (Pb) as a Contaminant of Poorly Regulated Kratom Products in the United States. Toxics 10:7, pages 398.
Crossref
Amanda L A Mohr, Barry K Logan, Melissa F Fogarty, Alex J Krotulski, Donna M Papsun, Sherri L Kacinko, Marilyn A Huestis & Jeri D Ropero-Miller. (2022) Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review. Journal of Analytical Toxicology 46:6, pages e116-e185.
Crossref
Norsyifa Harun, Nur Azzalia Kamaruzaman, Zarif Mohamed Sofian & Zurina Hassan. (2022) Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy. Neuroscience Letters 773, pages 136500.
Crossref
Mohammad Farris Iman Leong Bin Abdullah & Darshan Singh. (2021) The Adverse Cardiovascular Effects and Cardiotoxicity of Kratom (Mitragyna speciosa Korth.): A Comprehensive Review. Frontiers in Pharmacology 12.
Crossref
Walter C. Prozialeck, Peter C. Lamar, Michael KruppIIII, Matthew Moon, Laura E. Phelps & Oliver Grundmann. (2021) Kratom Use Within the Context of the Evolving Opioid Crisis and the COVID-19 Pandemic in the United States. Frontiers in Pharmacology 12.
Crossref
Alessandro E. Vento, Simone de Persis, Sergio De Filippis, Fabrizio Schifano, Flavia Napoletano, John M. Corkery & Georgios D. Kotzalidis. (2021) Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. Frontiers in Psychiatry 12.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.